association of typical versus atypical antipsychotics with symptoms and quality of life in schizophrenia协会的典型和非典型抗精神病药物与精神分裂症症状和生活质量.pdf

Association of Typical versus Atypical Antipsychotics with Symptoms and Quality of Life in Schizophrenia 1 2 3 Koichiro Fujimaki *, Terumichi Takahashi , Shigeru Morinobu 1 Faculty of Health and Welfare, Prefectural University of Hiroshima, Hiroshima, Japan, 2 Mihara Hospital, Hiroshima, Japan, 3 Programs for Biomedical Research, Division of Frontier Medical Science, Department of Psychiatry and Neurosciences, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan Abstract Background: Several reports on patients with chronic schizophrenia suggest that atypical versus typical antipsychotics are expected to lead to better quality of life (QOL) and cognitive function. Our aim was to examine the association of chronic treatment with typical or atypical antipsychotics with cognitive function, psychiatric symptoms, QOL, and drug-induced extrapyramidal symptoms in long-hospitalized patients with schizophrenia. Methodology and Principal Findings: The Hasegawa Dementia Scale-Revised (HDS-R), Brief Psychiatric Rating Scale (BPRS), the Schizophrenia Quality of Life Scale, translated into Japanese (JSQLS), and the Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS) were used to evaluate cognitive function, psychiatric symptoms, QOL, and drug-induced extrapyramidal symptoms. We examined the correlation between the dose of antipsychotics and each measure derived from these psychometric tests. The student t-test was used to compare scores obtained from psychometric tests between patients receiving typical and atypical antipsychotics. Results showed significant correlations between chlorpromazine (CPZ)- equivalent doses of typical antipsychotics and atypical antipsychotics, and the total BPRS s